stoxline Quote Chart Rank Option Currency Glossary
GT Biopharma, Inc. (GTBP)
3.69  -0.18 (-4.65%)    04-19 16:00
Open: 3.8
High: 3.8
Volume: 5,860
Pre. Close: 3.87
Low: 3.65
Market Cap: 5(M)
Technical analysis
2024-04-19 5:09:52 PM
Short term     
Mid term     
Targets 6-month :  5.37 1-year :  6.08
Resists First :  4.59 Second :  5.21
Pivot price 4.05
Supports First :  3.6 Second :  3
MAs MA(5) :  3.79 MA(20) :  4.14
MA(100) :  5.55 MA(250) :  7.25
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  17.5 D(3) :  15.9
RSI RSI(14): 39.1
52-week High :  16.11 Low :  3.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GTBP ] has closed above bottom band by 14.7%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.81 - 3.83 3.83 - 3.85
Low: 3.59 - 3.61 3.61 - 3.64
Close: 3.65 - 3.69 3.69 - 3.73
Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Headline News

Wed, 27 Mar 2024
GT Biopharma Inc Down 3.44% To $4.33 After Earnings Beat - InvestorsObserver

Fri, 02 Feb 2024
GT Biopharma Announces 1-for-30 Reverse Stock Split - - TipRanks

Fri, 02 Jun 2023
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Mon, 15 Nov 2021
GT Biopharma: Therapy Strategy Shift Reduces Attractiveness (NASDAQ:GTBP) - Seeking Alpha

Mon, 13 Sep 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies - PR Newswire

Tue, 03 Aug 2021
This Biotech Stock was Once a Penny Stock but is Now Making Big Moves on the Nasdaq! - Penny Stocks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 10.4 (%)
Held by Institutions 13.4 (%)
Shares Short 9 (K)
Shares Short P.Month 6 (K)
Stock Financials
EPS -5.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.4
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -55.1 %
Return on Equity (ttm) -79.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.67
PEG Ratio 0
Price to Book value 0.68
Price to Sales 0
Price to Cash Flow -0.58
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android